Multiple sclerosis (MS) affects around 700,000 people in Europe, of which around 96,000 suffer from the primary progressive form, which causes severe disability. Most people diagnosed with MS suffer from either recurrent (RMS) or primary progressive (PPMS) at the time of diagnosis.
Until this drug, people with primary progressive multiple sclerosis (PPMS), who often had to travel with a cane or wheelchair, quit their jobs, and require special care, had no approved treatments to slow the progression of the disease. People with recurrent-remissive multiple sclerosis (MS) often had to choose between greater safety and efficacy of treatment. This drug is given once every six months, without the need for constant monitoring, which will hopefully help people live their lives without thinking about treatment on a daily basis, “said Gavin Giovannoni, Professor of Neurology at Barts. . and the London School of Medicine and Dentistry, Queen Mary University of London.
The drug has important benefits for patients with primary progressive multiple sclerosis in the early stages, is an important option for those suffering from recurrent forms of multiple sclerosis, and is manufactured by Roche.